Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Zychma, M. J.
Right arrow Articles by Grzeszczak, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zychma, M. J.
Right arrow Articles by Grzeszczak, W.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (2000) 15: 1965-1970
© 2000 European Renal Association-European Dialysis and Transplant Association

Angiotensinogen M235T and chymase gene CMA/B polymorphisms are not associated with nephropathy in type II diabetes

Marcin J. Zychma, Ewa Zukowska-Szczechowska, Beata I. Lacka and Wladyslaw Grzeszczak

Department and Clinic of Internal Medicine and Diabetology, Silesian School of Medicine, Zabrze, Poland

Background. Several studies have suggested that the same genetic factors may be involved in the predisposition to both essential hypertension and diabetic nephropathy, but the molecular mechanism underlying this predisposition still remains unclear. In particular, the role of genes involved in blood-pressure regulation and angiotensin II action is still controversial. This study examines a possible association between angiotensinogen M235T and chymase gene CMA/B polymorphisms with the presence of nephropathy in type II diabetic Caucasians.

Methods. For the purposes of the study, 323 microalbuminuric and 127 overt proteinuric cases, together with 243 normoalbuminuric controls with long-duration diabetes were selected from a group of 941 type II diabetic patients with established renal status.

Results. No differences in the genotype distributions or allele frequencies of the examined polymorphisms between the study groups were observed. The study groups were also stratified by gender, diabetes duration, level of glycaemic control, body mass index, hypertension, and retinopathy status, but still no distortion in the distributions of genotypes of any of the examined polymorphisms in any of the strata was shown.

Conclusions. Our study provided evidence against an association between angiotensinogen M235T or chymase gene CMA/B polymorphisms and the presence of incipient or overt nephropathy in Caucasian patients with type II diabetes.

Keywords: angiotensinogen; chymase; genetics; nephropathy; NIDDM; polymorphisms

Correspondence and offprint requests to: Wladyslaw Grzeszczak, Department and Clinic of Internal Medicine and Diabetology, Silesian School of Medicine, 3-Maja 13-15, 41-800 Zabrze, Poland.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Ther Adv Cardiovasc DisHome page
S. Maeda
Review: Genetics of diabetic nephropathy
Therapeutic Advances in Cardiovascular Disease, October 1, 2008; 2(5): 363 - 371.
[Abstract] [PDF]


Home page
CJASNHome page
P. Ruggenenti, P. Bettinaglio, F. Pinares, and G. Remuzzi
Angiotensin Converting Enzyme Insertion/Deletion Polymorphism and Renoprotection in Diabetic and Nondiabetic Nephropathies
Clin. J. Am. Soc. Nephrol., September 1, 2008; 3(5): 1511 - 1525.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.